Università degli Studi di Torino (UNITO)
Founded in 1404, the University of Torino (UniTo) is one of the largest Italian Universities, with over 81.000 students, 6.2% of which of non-Italian citizenship, around 4.000 employees (academic, administrative and technical staff), more than 1.300 PhD students and more than 580 research fellows. Research and training are performed in 27 Departments, encompassing all scientific disciplines except engineering and architecture. The University activities are carried out in more than 100 venues in the whole Region, including 71 labs and infrastructures and 22 libraries with full access to the web, the Botanical Garden and a number of University Museums.
Today, the University of Torino offers over 150 undergraduate and graduate degree programs in almost every field of study involving about 5,000 international students (a.y. 2022-2023). A growing number of programs are taught in English, and Italian language tuition is available for incoming students. Doctoral school provides 54 doctoral programs.
UniTo manages roughly 500 research projects per year. The long record of participation of UniTo in the EU strategic research agenda results from 115 FP7 and 176 H2020 funded research projects. Under H2020, UniTo coordinated 40 projects and 13 ERC, out of which 3 Starting Grant, 8 Consolidator, 1 Advanced and 1 Synergy. UniTo took part in 42 Marie Skłodowska Curie Actions and 9 Research Infrastructures projects overall. In Horizon Europe, 45 projects have been financed so far: 10 of them are coordinated by UniTo and 8 have been funded under the Research Infrastructures programme.
UNITO is engaged in WP2 “Exploration of biomarkers to detect clinically relevant outcomes and death in high-risk populations”
TEAM MEMBERS
Dr Elisabetta Bugianesi
Dr. Bugianesi MD, PhD, is Full Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. Dr Bugianesi is an international acknowledged expert on Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) with over 20-years of experience. She contributed in the field with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH. Her contribution to science is testified by over 350 publications, an H Index = 86 (Scopus), N. Citations = 53830. She is the PI of the UNITO center for enrolment of patients with MASH and development/validation of non invasive biomarkers of liver damage.
Dr Chiara Rosso
Chiara Rosso is a Biologist at the Hepatology and Gastroenterology Lab. of the Department of Medical Sciences, University of Torino. Her research is focused on the pathogenetic mechanisms involved in the progression of MASLD, mainly through the measurement and validation of non-invasive biomarkers of liver fibrosis. She will be responsible for biological samples collection/processing/storage and of clinical data collection for the WP2.
Dr Gian Paolo Caviglia
Gian Paolo Caviglia is a Biologist at the Hepatology and Gastroenterology Lab. of the Department of Medical Sciences, University of Torino. His research is focused on the identification of biomarkers and tools for risk stratification of liver-related events in patients with advanced liver disease. He will be involved in biological samples collection/processing/storage and clinical data collection for the WP2.
Prof Davide Giuseppe Ribaldone
Davide Giuseppe Ribaldone is Associate professor at the Department of Medical Sciences, University of Torino, and gastroenterologist consultant at "A.O.U. Città della Salute e della Scienza di Torino" - "Molinette" hospital. He will participate in the recruitment of patients for WP2.
ALL THE CONSORTIUM